Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38659657 | 1.00 | POLB (0.50) | POLBHSD17B10FFAR1FFAR4HTT | |
| SCHEMBL19257272 | 0.93 | POLB (0.50) | POLBHSD17B10FFAR1HTTS1PR1 | |
| SCHEMBL15602007 | 0.91 | POLB (0.46) | POLBHSD17B10FFAR1FFAR4HTT | |
| SCHEMBL15602073 | 0.91 | RAB9A (0.44) | POLBHSD17B10FFAR1MAPTMTNR1A | |
| SCHEMBL19257588 | 0.91 | HSD17B10 (0.43) | POLBHSD17B10FFAR1MAPTMTNR1A | |
| SCHEMBL12660792 | 0.90 | POLB (0.52) | POLBHSD17B10FFAR1FFAR4HTT | |
| SCHEMBL19209443 | 0.88 | S1PR1 (0.51) | POLBHSD17B10S1PR1 | |
| SCHEMBL38659061 | 0.87 | MTNR1A (0.42) | HSD17B10FFAR1MTNR1AMTNR1B | |
| SCHEMBL1890644 | 0.87 | MTNR1A (0.42) | HSD17B10FFAR1MTNR1AMTNR1B | |
| SCHEMBL19257560 | 0.86 | POLB (0.46) | POLBHSD17B10FFAR1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | UNIVERSITAT DE VALENCIA (ES) | 2016-06-30 | — | — | US | claimed |
| EP-2496544-B1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN S L (SE) | 2014-08-20 | — | — | EP | claimed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | claimed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | claimed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20170204197-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | FIBROSTATIN S L (ES) | 2017-07-20 | — | — | US | disclosed |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | UNIVERSITAT DE VALENCIA (ES) | 2016-06-30 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | FIBROSTATIN, S.L. (ES) | 2015-11-12 | — | — | US | disclosed |
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | disclosed |
| WO-2015044352-A1 | GOODPASTURE ANTIGEN BINDING PROTEIN DETECTION AND INHIBITION AND ITS USE IN DIABETES | FIBROSTATIN, S.L. (ES) | 2015-04-02 | — | — | WO | disclosed |
| US-20150093378-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | FIBROSTATIN, S.L. (ES) | 2015-04-02 | — | — | US | disclosed |
| EP-2496544-B1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN S L (SE) | 2014-08-20 | — | — | EP | disclosed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | disclosed |
| WO-2014006020-A1 | GPBP-1 INHIBITION AND ITS THERAPEUTIC USE | FIBROSTATIN, S.L. (ES) | 2014-01-09 | — | — | WO | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204197-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | CD2BP2, SAP30BP, LY96 | POLB 3109/4885HSD17B10 2470/4885FFAR1 3034/4885 |
| US-20150093378-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | CD2BP2, SAP30BP, LY96 | POLB 3109/4885HSD17B10 2470/4885FFAR1 3034/4885 |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | POLB 2317/4885HSD17B10 2800/4885FFAR1 2951/4885 |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | POLB 2317/4885HSD17B10 2800/4885FFAR1 2951/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | POLB 2317/4885HSD17B10 2800/4885FFAR1 2951/4885 |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | VIM, EPCAM, CDH1 | POLB 3902/4885HSD17B10 3920/4885FFAR1 4443/4885 |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | POLB 2818/4885HSD17B10 3473/4885FFAR1 2553/4885 |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | POLB 2317/4885HSD17B10 2800/4885FFAR1 2951/4885 |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | POLB 2317/4885HSD17B10 2800/4885FFAR1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.